Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00138125 · ClinicalTrials.gov registry record · Phase 2
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
A Phase 2 study, sponsored by Translational Oncology Research International.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00138125 is a Phase 2 study that was terminated before completion, run by Translational Oncology Research International. The registered enrollment target is 2 participants.
The verdict
NCT00138125, a Phase 2 study, was terminated before completion, sponsored by Translational Oncology Research International.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving fulvestrant together with trastuzumab is more effective than giving fulvestrant or trastuzumab alone in treating breast cancer. PURPOSE: This randomized phase II trial is studying how well fulvestrant and/or trastuzumab works as first-line therapy in treating postmenopausal women with stage IV breast cancer.
Interventions
- BIOLOGICAL Herceptin
- DRUG Faslodex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00138125
The ClinicalTrials.gov registry entry for NCT00138125 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Oncology Research International, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Herceptin is the first listed.
NCT00138125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00138125 about?
NCT00138125 is a clinical study titled "Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer". RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to...
What is the current status of trial NCT00138125?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2005-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00138125?
The interventions under investigation include: Herceptin (BIOLOGICAL), Faslodex (DRUG).
Who is sponsoring clinical trial NCT00138125?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.